News | March 06, 2009

New ECG Technology Can Derive 22-Lead Function From Five Electrodes

March 6, 2009 – VectraCor Inc. submitted its 510(k) application to the FDA in December for a new technology to derive 22-lead ECG function from only five electrodes

VectraCor said its VectraplexECG will allow the calculation of a 12, 16, 19, or 22 lead ECG (n-lead ECG) from the measurement of three standard ECG leads that are acquired from just five electrodes. The company said it is the first to that can detect in real time an acute myocardial infarction with the same five electrodes.

According to the American Heart Association (AHA), in 2005 about 80.7 million Americans had one or more forms of cardiovascular disease (CVD), and this number is expected to rise as the population continues to age adding increased cost pressure to a healthcare system already financially challenged. The cost of cardiovascular diseases and stroke in 2008 is estimated by the American Heart Association at $448.5 billion which is almost a quarter of the annual $2 trillion estimated healthcare dollar. VectraCor said its patented technology will have a significant impact on lowering diagnostic costs while improving cardiac diagnosis and patient care in the CVD sector.

The standard of care for any patient entering any acute care setting, such as an emergency department, with a potential cardiac condition includes connecting the patient to a cardiac rhythm monitor. The purpose of the cardiac monitoring device is to measure the heart rate and identify the presence or absence of an arrhythmia. In connecting the cardiac monitor to the patient, three to five electrodes are placed on the patient’s torso. In addition, every patient with a potential cardiac disorder will receive a standard 12-lead resting electrocardiogram (ECG), which is measured with the placement of 10 additional electrodes using a different portable stand-alone machine that requires a technician, nurse, or physician for acquisition.

The VectraplexECG can eliminate the additional leads and separate monitoring device. Additionally, VectraCor said its technology will incorporate the world’s first patented “electrical cardiac marker” (VectraplexAMI) that in real-time will detect whether a patient is developing an acute myocardial infarction (AMI). The VectraplexAMI will be displayed on the cardiac monitor as a number in real-time, in the same manner as the heart rate. If the patient begins to develop an AMI, the electrical marker index displayed on the cardiac monitor will change, setting up an internal and audible alarm that will result in the automatic printout of the derived n-lead ECG for interpretation by the physician. This immediate feedback will enhance the efficiency of diagnosis. For the Holter ,onitor, this will be the first time a product will alarm to notify the patient that they may be having an AMI, and when the patient arrives at the hospital or doctor’s office, the staff can print up to a 22 lead ECG.

The company said its technology embedded in any existing or new ECG or cardiac monitor will deliver a derived 12-22 lead ECG from a three lead (four to five electrode) configuration (the standard ECG consists of 12 leads acquired from 10 body surface electrodes) on demand, reducing the need for a technician managed mobile ECG system and eliminating excess electrode placement. The company said fewer electrodes also would translate into reducing the ECG acquisition error due to the variability of electrode placement.

VectraCor said its technology uses advanced mathematical models to derive ECGs with 98-99 percent accuracy. In development for more than 25 years, the company has examined in excess of 700 ECGs in proving the reliability of the system and the validity of the information produced.

For more information: www.vectracor.com

Related Content

ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG| December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Heart Test Laboratories, HTL, MyoVista ECG, common stock offering
News | ECG| January 31, 2017
Heart Test Laboratories Inc. (HTL) has successfully raised $12 million by way of a Common Stock private placement...
AirStrip One, ECG management, web client, U.S. clearance
Technology | ECG| October 11, 2016
The U.S. Food and Drug Administration (FDA) has issued 510(K) Class II clearance to a web client for the AirStrip One...
Carestream, Vue Motion universal viewer, ECG waveforms, diagnostic reading, FDA clearance

Image courtesy of Carestream Health

Technology | ECG| November 20, 2015
Carestream has obtained U.S. Food and Drug Administration (FDA) clearance for diagnostic reading of electrocardiogram (...
CardioSecur mobile ECG, 22-lead, 360 degree view of the heart, CardioSecur Pro

Image courtesy of CardioSecur

Technology | ECG| October 08, 2015
Personal MedSystems introduced the first and only 22-lead mobile electrocardiogram (ECG) system, CardioSecur, at the...
Mortara, ELI 280, TouchScreen ECG, ECG advances, new ECG technology

The Mortara Eli 280 is part of a new generation of ECG systems that integrate touchscreen monitors to improve workflow.

Feature | ECG| September 16, 2015 | Dave Fornell
The resting electrocardiogram (ECG) has been us
zebrafish, iWorx Systems Inc., ZS-200 Zebrafish ECG System, cardiac research
Technology | ECG| August 13, 2015
iWorx Systems Inc., developer of advanced physiology teaching and research instruments and software, has introduced a...
Overlay Init